Valuation: Pluristem Therapeutics

Market Cap 1.48Cr 1.33Cr 1.22Cr 1.11Cr 2.07Cr 140.66Cr 2.11Cr 15Cr 5.84Cr 74Cr 5.56Cr 5.44Cr 233.34Cr P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 4.19Cr 3.75Cr 3.45Cr 3.13Cr 5.85Cr 398.07Cr 5.96Cr 41Cr 17Cr 209.4Cr 16Cr 15Cr 660.36Cr EV / Sales 2025
3,90,78,124x
EV / Sales 2026 4,89,16,935x
Free-Float
50.72%
Yield 2025 *
-
Yield 2026 -

Last Transcript: Pluristem Therapeutics

Manager TitleAgeSince
Chief Executive Officer 54 29/03/2017
Director of Finance/CFO 42 01/12/2022
Chief Operating Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 54 01/02/2015
Director/Board Member 56 06/01/2021
Director/Board Member 64 01/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
+3.38%-1.33% - - 1.48Cr
-0.62%+0.50%+33.92%+60.07% 6.44TCr
+0.35%+3.20%+14.92%+84.55% 5.62TCr
+0.53%+1.96%+15.37%+106.81% 5.42TCr
-2.80%-4.82%+22.83%+50.08% 4.53TCr
-0.36%-2.21%+19.81%+97.89% 4.22TCr
+0.59%+2.33%+225.04%+942.78% 4.08TCr
+3.27%+47.96%+112.67%+96.48% 3.38TCr
+1.22%-1.39%+13.92%+46.95% 3.22TCr
-1.29%-1.72%+21.00%-6.85% 2.36TCr
Average +0.41%+4.72%+53.27%+164.31% 4.36TCr
Weighted average by Cap. +0.00%+3.64%+50.05%+162.65%

Financials

2025 2026
Net sales 1.34 1.2 1.1 1 1.86 126.85 1.9 13.12 5.27 66.73 5.01 4.91 210.44 1.02 0.91 0.84 0.76 1.42 96.47 1.44 9.98 4.01 50.75 3.81 3.73 160.03
Net income -2.26Cr -2.02Cr -1.86Cr -1.69Cr -3.15Cr -214.43Cr -3.21Cr -22Cr -8.91Cr -112.79Cr -8.48Cr -8.29Cr -355.71Cr -2.38Cr -2.13Cr -1.96Cr -1.78Cr -3.32Cr -226.18Cr -3.39Cr -23Cr -9.39Cr -118.98Cr -8.94Cr -8.75Cr -375.21Cr
Net Debt 1.34Cr 1.2Cr 1.11Cr 1Cr 1.87Cr 127.59Cr 1.91Cr 13Cr 5.3Cr 67Cr 5.04Cr 4.94Cr 211.65Cr 2.71Cr 2.43Cr 2.23Cr 2.02Cr 3.78Cr 257.41Cr 3.85Cr 27Cr 11Cr 135.41Cr 10Cr 9.96Cr 427.02Cr
Logo Pluristem Therapeutics
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-